tiprankstipranks
Knight Therapeutics (DE:04K)
FRANKFURT:04K
Germany Market
04K
Knight Therapeutics
RESEARCH TOOLSreports

Knight Therapeutics (04K) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

04K Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Knight
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

04K Stock 12 Month Forecast

Average Price Target

€7.05
▲(19.53% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Knight Therapeutics in the last 3 months. The average price target is €7.05 with a high forecast of €7.47 and a low forecast of €6.84. The average price target represents a 19.53% change from the last price of €5.90.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","5":"€5","8":"€8","3.5":"€3.5","6.5":"€6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.46713068,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€7.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.052290086666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€7.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.84486979,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.84</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,3.5,5,6.5,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,6.112856206153846,6.225712412307693,6.338568618461538,6.451424824615385,6.564281030769231,6.677137236923077,6.7899934430769235,6.902849649230769,7.015705855384615,7.128562061538462,7.241418267692308,7.3542744738461545,{"y":7.46713068,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,6.080945391282051,6.161890782564102,6.242836173846154,6.323781565128205,6.404726956410256,6.485672347692307,6.566617738974359,6.64756313025641,6.728508521538461,6.809453912820512,6.890399304102564,6.971344695384615,{"y":7.052290086666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6,6.064989983846154,6.129979967692307,6.194969951538462,6.259959935384615,6.324949919230769,6.389939903076923,6.454929886923077,6.519919870769231,6.584909854615384,6.649899838461538,6.7148898223076925,6.779879806153846,{"y":6.84486979,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.54,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.92,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.05,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€7.47Average Price Target€7.05Lowest Price Target€6.84
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bloom Burton Analyst forecast on DE:04K
David Martin PhD
Bloom Burton
Bloom Burton
€7.47
Buy
26.56%
Upside
Reiterated
08/07/26
Analyst Reiterates Buy on Knight Therapeutics, Citing Strong Q2 Beat, Raised Guidance and DCF-Supported C$12 Target Price
RBC Capital Analyst forecast on DE:04K
Douglas Miehm
RBC Capital
RBC Capital
€5.91→€6.84
Buy
16.01%
Upside
Reiterated
08/07/26
RBC Capital Remains a Buy on Knight Therapeutics (KHTRF)
Stifel Nicolaus Analyst forecast on DE:04K
Justin Keywood
Stifel Nicolaus
Stifel Nicolaus
€5.91→€6.84
Buy
16.01%
Upside
Reiterated
08/07/26
Knight Therapeutics price target raised to C$11 from C$9.50 at StifelKnight Therapeutics price target raised to C$11 from C$9.50 at Stifel
Canaccord Genuity Analyst forecast on DE:04K
Tania Armstrong-Whitworth
Canaccord Genuity
Canaccord Genuity
€5.91
Buy
0.19%
Upside
Initiated
05/08/26
Knight Therapeutics resumed with a Buy at CanaccordKnight Therapeutics resumed with a Buy at Canaccord
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bloom Burton Analyst forecast on DE:04K
David Martin PhD
Bloom Burton
Bloom Burton
€7.47
Buy
26.56%
Upside
Reiterated
08/07/26
Analyst Reiterates Buy on Knight Therapeutics, Citing Strong Q2 Beat, Raised Guidance and DCF-Supported C$12 Target Price
RBC Capital Analyst forecast on DE:04K
Douglas Miehm
RBC Capital
RBC Capital
€5.91→€6.84
Buy
16.01%
Upside
Reiterated
08/07/26
RBC Capital Remains a Buy on Knight Therapeutics (KHTRF)
Stifel Nicolaus Analyst forecast on DE:04K
Justin Keywood
Stifel Nicolaus
Stifel Nicolaus
€5.91→€6.84
Buy
16.01%
Upside
Reiterated
08/07/26
Knight Therapeutics price target raised to C$11 from C$9.50 at StifelKnight Therapeutics price target raised to C$11 from C$9.50 at Stifel
Canaccord Genuity Analyst forecast on DE:04K
Tania Armstrong-Whitworth
Canaccord Genuity
Canaccord Genuity
€5.91
Buy
0.19%
Upside
Initiated
05/08/26
Knight Therapeutics resumed with a Buy at CanaccordKnight Therapeutics resumed with a Buy at Canaccord
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
HITIHigh Tide
JAZZJazz Pharmaceuticals
OMCLOmnicell
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Knight Therapeutics

3 Months
Tania Armstrong-WhitworthCanaccord Genuity
Success Rate
11/16 ratings generated profit
69%
Average Return
+2.06%
Copying Tania Armstrong-Whitworth's trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +2.06% per trade.
1 Year
Douglas MiehmRBC Capital
Success Rate
17/27 ratings generated profit
63%
Average Return
+9.23%
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 62.96% of your transactions generating a profit, with an average return of +9.23% per trade.
2 Years
Douglas MiehmRBC Capital
Success Rate
18/27 ratings generated profit
67%
Average Return
+20.90%
Copying Douglas Miehm's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +20.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

04K Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
1
0
0
0
0
Buy
6
4
4
3
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
4
4
3
3
In the current month, 04K has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 04K average Analyst price target in the past 3 months is 7.05.
Each month's total comprises the sum of three months' worth of ratings.

04K Financial Forecast

04K Earnings Forecast

Next quarter’s earnings estimate for 04K is <€0.01 with a range of >-€0.01 to €0.02. The previous quarter’s EPS was -€0.02. 04K beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 04K has Performed in-line its overall industry.
Next quarter’s earnings estimate for 04K is <€0.01 with a range of >-€0.01 to €0.02. The previous quarter’s EPS was -€0.02. 04K beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 04K has Performed in-line its overall industry.

04K Sales Forecast

Next quarter’s sales forecast for 04K is €79.43M with a range of €73.35M to €81.97M. The previous quarter’s sales results were €89.49M. 04K beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 04K has Performed in-line its overall industry.
Next quarter’s sales forecast for 04K is €79.43M with a range of €73.35M to €81.97M. The previous quarter’s sales results were €89.49M. 04K beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 04K has Performed in-line its overall industry.

04K Stock Forecast FAQ

What is DE:04K’s average 12-month price target, according to analysts?
Based on analyst ratings, Knight Therapeutics’s 12-month average price target is 7.05.
    What is DE:04K’s upside potential, based on the analysts’ average price target?
    Knight Therapeutics has 19.53% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Knight Therapeutics a Buy, Sell or Hold?
          Knight Therapeutics has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Knight Therapeutics’s share price target?
            The average share price target for Knight Therapeutics is 7.05. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €7.47 ,and the lowest forecast is €6.84. The average share price target represents 19.53% Increase from the current price of €5.9.
              What do analysts say about Knight Therapeutics?
              Knight Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of Knight Therapeutics?
                To buy shares of DE:04K, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.